期刊文献+

非小细胞肺癌患者发病危险因素的logistic回归分析 被引量:42

下载PDF
导出
摘要 目的通过对本院非小细胞肺癌患者的发病危险因素进行分析,以期为非小细胞肺癌的预防和治疗提供依据。方法选取本院2015年1月至2017年1月收治的268例非小细胞肺癌患者作为观察组,选取同期收治的良性肺部疾病患者268例作为对照组,收集两组患者的年龄、性别、民族、吸烟、被动吸烟、家族恶性肿瘤史、呼吸系统疾病史、精神创伤史、职业暴露史、BMI等一般临床资料和相关资料,采用病例对照研究、单因素分析、多因素logistic分析等方法对其进行统计分析,探讨影响非小细胞肺癌患者发病的危险因素。结果单因素分析结果显示,非小细胞肺癌发病的危险因素有年龄、BMI、吸烟、被动吸烟、家族恶性肿瘤史、呼吸系统疾病史、职业暴露史等;多因素分析结果显示,非小细胞肺癌发病的主要危险因素为吸烟(OR=4.361,P=0.005)、被动吸烟(OR=2.229,P=0.009)、家族恶性肿瘤史(OR=1.413,P=0.01)和职业暴露史(OR=2.883,P=0.009)。结论针对非小细胞肺癌的发病危险因素,采取相应的改善措施,预防非小细胞肺癌的发生。
作者 张美娟
机构地区 三亚市人民医院
出处 《中国卫生统计》 CSCD 北大核心 2020年第3期462-464,共3页 Chinese Journal of Health Statistics
  • 相关文献

参考文献3

二级参考文献29

  • 1Lally B E, Zeherman D, Colasanto J M, et al. Postoperative radiotherapy for stage Ⅱ or Ⅲ non-small-cell lung cancer using the surveillance, epidemiology, and end results database[J]. Clin Oncol, 2006,24(19) : 2998-3006.
  • 2Douillard J Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage I B- Ⅲ A non-small -cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA] ) : a randomised controlled trial[J]. Lancet Oncol, 2006,7 (9) : 719-727.
  • 3PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small -cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials[J]. Lancet, 1998,352(9124):257-263.
  • 4Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer[J].J Thorac Cardiovasc Surg, 1978, 76 : 832-839.
  • 5Daniel F, Nena M, Kathy SA. Multimodality therapy for stage Ⅲ non-small-cell lung cancer[J]. J Clin Oncol, 2005,23( 14):3257-3269.
  • 6International adjuvant lung cancer trial collaborative group:Cisplatin- based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer[J]. N Engl J Med,2004, 4(350) :351-360.
  • 7Winton T L, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer Intergroup[J]. N Engl J Med, 2005, 25 (352) : 2589-2597.
  • 8Betticher D C, Schmitz S F H, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stageⅢ A pN2 non-small-cen lungcancer: The 5-year follow-up of a phase II study [J]. Br J Cancer, 2006, 94 (8) : 1099-1106.
  • 9Machtay M, Lee JH, Shrager J B, et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma[J]. J Clin Oncol, 2001,19( 19 ) :3912-3917.
  • 10Wakelee H A, Stephenson P, Keller S M, et al. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages Ⅱ and Ⅲ A non-small cell lung cancer( NSCLC ) does not increase the expected risk of death from intercurrent disease(DID) in eastern cooperative oncology group (ECOG) trial E3590[J]. Lung Cancer, 2005,48 ( 3 ) : 389-397.

共引文献15

同被引文献603

引证文献42

二级引证文献149

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部